A 67-year old man was diagnosed with advanced prostate cancer with multiple pelvic lymph nodes and multiple bone metastases (cT2N1M1b), with an initial prostate specific antigen of 1, 300 ng/ml. Prostate biopsy specimens revealed poorly differentiated adenocarcinoma, Gleason’s score 5+3. He was treated with maximal androgen blockade (MAB) from 2001, but showed resistance to hormone therapy and docetaxel in 2007. External radiation therapy for bone pain was difficult due to multiple lesions. 89Sr therapy was started in 2009. The therapy could be performed 5 times without any side effects. Good pain control and decreasing PSA was obtained at each dose
A multicentre observational study was conducted by the Italian Association of Nuclear Medicine betwe...
Aim —to evaluate the clinical efficiency of strontium-89 chloride in the treatment of pain syndrome ...
Bone seeking radiopharmaceuticals are indicated in cancer patients with multiple painful skeletal me...
Hormone resistant phase of prostatic cancer develops after 16-24 months of hormone therapy of metast...
In patients with prostatic adenocarcinoma with bony metastasis, pain palliation is an important poin...
Abstract: Background: Strontium 89 (Sr89), a beta-emitter particle that precipitates in bone, has a ...
Aimof this study was to assessment of 89 Sr therapy as pain treatment modality in the group of patie...
A 60-year-old man visited the previous hospital with difficulty of urination in July 2004. Serum pro...
These retrospective study is aimed to evaluate the efficacy of therapy with Stronthium-chloride 89 (...
CASE SUMMARY: A 79-year-old man with prostate cancer previously treated in 1997 with radical prosta...
There are few options for treating painful bone metastasis in multiple sites. Hemibody irradiation, ...
# The Author(s) 2016. This article is published with open access at Springerlink.com Abstract Metast...
We present a case of gigantic prostate tumor in a patient with castration-resistant prostate cancer ...
Copyright © 2015 Shogo Hosogoe et al.This is an open access article distributed under the Creative C...
Prostate cancer is the second most common cancer in men in the UK. Androgen ablation with luteinisin...
A multicentre observational study was conducted by the Italian Association of Nuclear Medicine betwe...
Aim —to evaluate the clinical efficiency of strontium-89 chloride in the treatment of pain syndrome ...
Bone seeking radiopharmaceuticals are indicated in cancer patients with multiple painful skeletal me...
Hormone resistant phase of prostatic cancer develops after 16-24 months of hormone therapy of metast...
In patients with prostatic adenocarcinoma with bony metastasis, pain palliation is an important poin...
Abstract: Background: Strontium 89 (Sr89), a beta-emitter particle that precipitates in bone, has a ...
Aimof this study was to assessment of 89 Sr therapy as pain treatment modality in the group of patie...
A 60-year-old man visited the previous hospital with difficulty of urination in July 2004. Serum pro...
These retrospective study is aimed to evaluate the efficacy of therapy with Stronthium-chloride 89 (...
CASE SUMMARY: A 79-year-old man with prostate cancer previously treated in 1997 with radical prosta...
There are few options for treating painful bone metastasis in multiple sites. Hemibody irradiation, ...
# The Author(s) 2016. This article is published with open access at Springerlink.com Abstract Metast...
We present a case of gigantic prostate tumor in a patient with castration-resistant prostate cancer ...
Copyright © 2015 Shogo Hosogoe et al.This is an open access article distributed under the Creative C...
Prostate cancer is the second most common cancer in men in the UK. Androgen ablation with luteinisin...
A multicentre observational study was conducted by the Italian Association of Nuclear Medicine betwe...
Aim —to evaluate the clinical efficiency of strontium-89 chloride in the treatment of pain syndrome ...
Bone seeking radiopharmaceuticals are indicated in cancer patients with multiple painful skeletal me...